Recently, the Beijing Municipal Bureau of economy and information technology announced the list of "specialized and special new" small and medium-sized enterprises in Beijing. With professional R & D team, strong technical strength, continuous innovation ability and scientific enterprise management, our company successfully passed the recognition of "specialized and special new", which is also a high recognition of our efforts in specialization, refinement, characteristics and innovation, KeYue Zhongkai will also continue to provide new momentum for the development of biotechnology in our city.
"Specialized, special and new" small and medium-sized enterprises refer to small and medium-sized enterprises with the characteristics of "specialization, refinement, characteristics and novelty". Further refinement refers to the honorary awards specially established by the state to encourage small and medium-sized enterprises to realize the development of professional operation, refined output, characteristic technology and novel products. The award carries out comprehensive evaluation and professional review on enterprises from multiple dimensions such as operating income, operating profit, R & D investment, innovation ability, market occupancy and intellectual property rights. Beijing KeYue Zhongkai Biotechnology Co., Ltd., as a leading technology enterprise focusing on the supply of IVD antigen and antibody and other raw materials for more than ten years, has always adhered to technological innovation and high-quality product development, and has continuously passed the ISO9001 quality management system certification. It is a member of China Pharmaceutical Biotechnology Association; It has many honors such as "high-tech enterprise", "scientific and technological small and medium-sized enterprise" and "double independent enterprise" of the state and Zhongguancun. At present, the company has applied for 5 national invention patents and obtained 17 registered trademarks. There are more than 20 projects under research, which have been rated as "tax credit class a enterprise" for 7 consecutive years.
In the future, KeYue Zhongkai will continue to adhere to the development idea of independent innovation, adhere to the development route of specialization, refinement, characteristics and novelty, launch more high-quality products and make greater contributions to the field of biotechnology in China.